We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sarepta Looks to Focus on Exondys 51 & DMD Pipeline in 2017
Read MoreHide Full Article
We issued an updated research report on Cambridge, MA-based Sarepta Therapeutics, Inc. (SRPT - Free Report) on Jun 28.
Sarepta is a commercial-stage biopharmaceutical company that focuses on the discovery and development of RNA-based therapeutics targeting rare and infectious diseases, especially Duchenne muscular dystrophy (DMD).
So far this year, Sarepta’s share price has outperformed the Zacks categorized Medical-Biomed/Genetics industry. The stock has surged 21.6% compared with an increase of 10.0% for the broader industry.
Sarepta received a boost with the FDA’s accelerated approval for Exondys 51 (eteplirsen) in the U.S. in Sep 2016. Exondys 51 is the first approved disease-modifying therapy for DMD in the U.S. as well as the company’s first product to receive marketing approval. The drug is under review in the EU.
The company is conducting a confirmatory phase III study - PROMOVI - evaluating the clinical benefits of the drug as part of the accelerated approval process. The study evaluates whether Exondys 51 improves motor function in DMD patients with a confirmed mutation of the dystrophin gene amenable to exon 51 skipping.
In the first quarter, Sarepta recorded revenues of $16.3 million, up 201% sequentially, primarily due to sales of Exondys 51. Also, the company recognized a narrower per share loss of 70 cents from the year-ago loss of $1.31. However, selling, general & administrative (SG&A) expenses have increased due to higher legal fees and commercial initiatives, compensation and other personnel expenses related to commercialization of Exondys 51.
Moreover, based on sales trends witnessed in the first quarter, the company expects Exondys 51 to generate $95 million in revenues in 2017, exceeding its prior guidance of $80 million.
Meanwhile, Sarepta is focused on building its DMD pipeline beyond Exondys 51. The company has eight exon-skipping candidates in its pipeline that is estimated to treat 75%–80% of the DMD population. The company is also evaluating candidates targeting exon 53 (Study 4053-101—6 to15 years, ambulatory; data expected this year) and exon 45/53 (Study 4045-301—7 to16 years, ambulatory). In addition, Sarepta is conducting Study 4045-101 in non-ambulatory boys aged 7 to 21 years amenable to skipping-exon-45.
Meanwhile, after the approval of its DMD drug, Sarepta collaborated with Catabasis Pharmaceuticals in 2016 to conduct a joint research to explore a combination-drug treatment approach for DMD.
Apart from DMD, the company develops treatments for infectious diseases including Marburg virus, Ebola virus and influenza, which is primarily funded and supported by the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID). Along with it, Sarepta has an exclusive license and collaboration agreement with Summit Therapeutics plc (SMMT - Free Report) for the rights to the latter’s utrophin modulator pipeline.
However, Pfizer Inc. (PFE - Free Report) , BioMarin, PTC Therapeutics, Inc. (PTCT - Free Report) and many more are developing RNA-based treatments for DMD. With small and major companies developing their own pipeline, the DMD market is set to become competitive in the future.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Sarepta Looks to Focus on Exondys 51 & DMD Pipeline in 2017
We issued an updated research report on Cambridge, MA-based Sarepta Therapeutics, Inc. (SRPT - Free Report) on Jun 28.
Sarepta is a commercial-stage biopharmaceutical company that focuses on the discovery and development of RNA-based therapeutics targeting rare and infectious diseases, especially Duchenne muscular dystrophy (DMD).
So far this year, Sarepta’s share price has outperformed the Zacks categorized Medical-Biomed/Genetics industry. The stock has surged 21.6% compared with an increase of 10.0% for the broader industry.
Sarepta received a boost with the FDA’s accelerated approval for Exondys 51 (eteplirsen) in the U.S. in Sep 2016. Exondys 51 is the first approved disease-modifying therapy for DMD in the U.S. as well as the company’s first product to receive marketing approval. The drug is under review in the EU.
The company is conducting a confirmatory phase III study - PROMOVI - evaluating the clinical benefits of the drug as part of the accelerated approval process. The study evaluates whether Exondys 51 improves motor function in DMD patients with a confirmed mutation of the dystrophin gene amenable to exon 51 skipping.
In the first quarter, Sarepta recorded revenues of $16.3 million, up 201% sequentially, primarily due to sales of Exondys 51. Also, the company recognized a narrower per share loss of 70 cents from the year-ago loss of $1.31. However, selling, general & administrative (SG&A) expenses have increased due to higher legal fees and commercial initiatives, compensation and other personnel expenses related to commercialization of Exondys 51.
Moreover, based on sales trends witnessed in the first quarter, the company expects Exondys 51 to generate $95 million in revenues in 2017, exceeding its prior guidance of $80 million.
Meanwhile, Sarepta is focused on building its DMD pipeline beyond Exondys 51. The company has eight exon-skipping candidates in its pipeline that is estimated to treat 75%–80% of the DMD population. The company is also evaluating candidates targeting exon 53 (Study 4053-101—6 to15 years, ambulatory; data expected this year) and exon 45/53 (Study 4045-301—7 to16 years, ambulatory). In addition, Sarepta is conducting Study 4045-101 in non-ambulatory boys aged 7 to 21 years amenable to skipping-exon-45.
Meanwhile, after the approval of its DMD drug, Sarepta collaborated with Catabasis Pharmaceuticals in 2016 to conduct a joint research to explore a combination-drug treatment approach for DMD.
Apart from DMD, the company develops treatments for infectious diseases including Marburg virus, Ebola virus and influenza, which is primarily funded and supported by the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID). Along with it, Sarepta has an exclusive license and collaboration agreement with Summit Therapeutics plc (SMMT - Free Report) for the rights to the latter’s utrophin modulator pipeline.
However, Pfizer Inc. (PFE - Free Report) , BioMarin, PTC Therapeutics, Inc. (PTCT - Free Report) and many more are developing RNA-based treatments for DMD. With small and major companies developing their own pipeline, the DMD market is set to become competitive in the future.
Sarepta Therapeutics, Inc. Price and Consensus
Sarepta Therapeutics, Inc. Price and Consensus | Sarepta Therapeutics, Inc. Quote
Zacks Rank
Sarepta currently holds Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>